CoChat

Ibudilast for the treatment of drug addiction and other neurological conditions

Johnson, Kirk W, Matsuda, Kazuko, Iwaki, Yuichi · 2014 · Clinical Investigation
Cited by 29

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Ibudilast is a small molecular weight, orally administered compound that was originally developed and approved in Japan over 20 years ago for bronchial asthma and poststroke complication (subsequently defined as poststroke dizziness in 2002). Over the last 10 years, there has been substantial progress in better understanding ibudilast’s molecular and cellular actions including macrophage migration inhibitory factor inhibition, phosphodiesterase inhibition and attenuation of activated glia. Moreover, its potential safety and efficacy in new neurological indications has been explored via animal models and Phase I and II clinical studies. Phase II clinical trials have now initiated in methamphetamine and other drug addictions, progressive multiple sclerosis and pain. A current model of ibudilast target action and a review of its translational progress and prospects as a new medication in these disorders is described.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4155/cli.14.8

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 45

  1. 10.3109/02770909209048938 · DOI · Paper page
  2. Fukuyama, 1993, Neurol. Res., 15, 169, 10.1080/01616412.1993.11740130 · doi:10.1080/01616412.1993.11740130
  3. 10.1517/13543784.16.7.935 · DOI · Paper page
  4. 10.1517/14656560903426189 · DOI · Paper page
  5. 10.1212/WNL.0b013e3181d7d651 · DOI · Paper page
  6. 10.1017/S1740925X0700035X · DOI · Paper page
  7. 10.3109/00498250903254340 · DOI
  8. 10.1073/pnas.1002716107 · DOI · Paper page
  9. 10.1016/j.ejphar.2006.02.053 · DOI
  10. 10.1074/jbc.M112.385070 · doi:10.1074/jbc.m112.385070
  11. 10.1016/S0006-8993(99)01666-2 · DOI
  12. 10.1016/j.bbi.2008.09.012 · DOI · Paper page
  13. 10.1038/nrd1251 · DOI · Paper page
  14. Romero-Sandoval, 2008, Curr. Opin. Investig. Drugs., 9, 726
  15. 10.1016/j.bbi.2008.09.004 · DOI · Paper page
  16. Bar-Or, 2010, Int.J. MS Care, 12, 16
  17. 10.1038/jcbfm.2009.261 · DOI · Paper page
  18. 10.1007/s00213-010-2014-5 · DOI · Paper page
  19. 10.1196/annals.1441.032 · DOI · Paper page
  20. 10.1016/j.drudis.2012.12.013 · DOI
  21. 10.1016/j.neuropharm.2003.09.009 · DOI · Paper page
  22. 10.1111/j.1530-0277.2011.01722.x · DOI · Paper page
  23. 10.1016/j.ejphar.2013.01.016 · DOI · Paper page
  24. 10.1016/j.bbi.2009.01.014 · DOI · Paper page
  25. Bell, 2013, Addict. Biol.
  26. 10.1016/j.genhosppsych.2009.12.005 · DOI
  27. 10.1212/WNL.0b013e3181d6b165 · doi:10.1212/wnl.0b013e3181d6b165
  28. Ellis, 2008, Soc. Neuroscience
  29. 10.1007/s00401-008-0476-x · DOI
  30. 10.1097/ALN.0b013e31820a4bf3 · DOI
  31. 10.1016/S0165-5728(98)00251-3 · DOI
  32. 10.1186/1742-2094-2-10 · DOI
  33. Powell, 2005, J. Immunol., 175, 5611, 10.4049/jimmunol.175.9.5611 · DOI
  34. 10.1096/fj.10-162347 · DOI
  35. 10.1038/jcbfm.2010.194 · DOI · Paper page
  36. 10.1111/j.1365-2125.2008.03270.x · DOI · Paper page
  37. 10.1007/s11065-007-9031-0 · DOI · Paper page
  38. ComerS, Saccone P, Johnson KW. A drug candidate for improving opioid analgesia and attenuating dependence and tolerance: an exploratory trial of ibudilast in morphine withdrawal and analgesia in heroin addicts. 80(Meeting Abstracts 1) (2013). · doi:10.1212/wnl.80.7_supplement.p07.183
  39. 10.1191/1352458504ms1070oa · DOI
  40. 10.1177/0333102412467512 · DOI
  41. 10.1016/j.mehy.2008.09.048 · DOI
  42. 10.1089/neu.2011.2273 · DOI
  43. 10.1016/j.mehy.2012.08.013 · DOI
  44. Rodgers, 2013, J. Neurotrauma.
  45. 10.1096/fj.12-214643 · DOI

Cited by

See all 29

Metadata

Authors
Johnson, K. W., Matsuda, K., & Iwaki, Y.
Venue
Clinical Investigation
Published
2014-03
Volume
4
Issue
3
Pages
269-279
ISSN
  • 2041-6792 (ISSN-L)
  • 2041-6806
OpenAlex
W2124142446
Cited by
29
References
4
FWCI
1.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.